EASD 2026 Key Press Releases (September 30)
On the third day of EASD 2026, four key news items were observed from Lilly, Zealand Pharma, Novo/Ro, and NewAmsterdam Pharma. Below, FENIX provides context and analysis for the announcements.
On the third day of EASD 2026, four key news items were observed from Lilly, Zealand Pharma, Novo/Ro, and NewAmsterdam Pharma. Below, FENIX provides context and analysis for the announcements.
On the second day of EASD 2026, seven key news items were observed from Novo/Hengrui, Lilly, Caspian Therapeutics, Merck/Cyprumed GmbH, and Oura. Below, FENIX provides context and analysis for the announcements.
On the first day of EASD 2026, six key news items were observed from Roche, Tandem Diabetes Care, Dexcom, Lilly, MindRank, and DreaMed Diabetes. Below, FENIX provides context and analysis for the announcements.
Part 3 of FENIX’s 2026 Novo CMD coverage recaps the company’s strategy to navigate and grow through the eventual sema LOE, arguably the biggest headwind in the company’s 100+ year history. Below, FENIX outlines several key factors that could influence Novo’s ability to navigate the difficult period, including the speculative hypothesis that Lilly gets to decide whether Novo will pursue generic tirzepatide.
With EASD 2026 approaching (September 28-October 2; Milan, Italy), FENIX has compiled a short list of key sessions and presentations that warrant close attention. While EASD brings new data and fresh perspectives across the cardiometabolic space each year, the list below focuses exclusively on the sessions with potential to shape this year’s conference narrative and ultimately have an outsized impact on the field for years to come.
Two cardiometabolic-related news items have been observed: Novo partnered with Nanexa to develop up to five ultra-long-acting obesity/T2DM assets (view press release), and Clywedog Therapeutics announced Ph1b data for its menin inhibitor in T2DM (view press release). Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from Lilly, BI/WHO, Roche/Atavistik Bio, Aqua Medical, Biolinq, and Rezera. Below, FENIX provides highlights and insights for the respective news items.
Two cardiometabolic-related news items have been observed: Wave Life Sciences initiated the Ph2a WVE-007 + tirzepatide combination arm of the INLIGHT study (view press release), and Abbott entered into a partnership with Berry Street for personalized nutrition insights with Lingo (view press release). Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from Viking Therapeutics, Roche, Lilly, NewAmsterdam Pharma, and Zealand Pharma. The news items seemingly come hot on the heels of Novo’s obesity-centric Capital Markets Day held Monday. Below, FENIX provides highlights and insights for the respective news items.
Part 2 of FENIX’s 2026 Novo CMD coverage recaps commentary on US commercial operations, global manufacturing & supply, and international operations. Each of these three components is viewed as integral to Novo’s future success while it attempts to maintain (and grow) its place in the CVRM market ahead of the onslaught of obesity competitors looking to eat its lunch.